Professional Summary
Specializing In
Practice Locations
Patient Ratings
Referring Physicians
Biography
Dr. Delitto is a board certified complex general surgical oncologist with a focus on conditions of the liver, pancreas, and stomach. He is an assistant professor in Stanford Medicine’s Department of Surgery.
His education includes a decade of postgraduate training in complex general surgical oncology, as well as a PhD in immunology with an emphasis on cancer biology. He completed a clinical fellowship at Johns Hopkins University and continued his research at the postdoctoral level in the laboratory of Dr. Elizabeth Jaffee. His research focus is on advancing the field of cancer immunology and harnessing his findings to improve immunotherapies.
He was the principal investigator of two studies examining the immune response to pancreatic cancer, including one funded by the National Cancer Institute.
Dr. Delitto has presented the findings of his research at conferences such as the American Association for Cancer Research, Society for the Immunotherapy of Cancer, American Association of Immunologists, American College of Surgeons, Academic Surgical Congress and Pancreas Club. In addition to cancer immunology, he has also presented work focused on cancer cachexia, surgical outcomes, translational experimental models and a variety of other oncologic topics.
He has published original work in Nature Communications, the Journal of the National Cancer Institute, Cancer Research, Clinical Cancer Research, and other high impact journals. He is also a reviewer for Annals of Surgery, Scientific Reports, Surgery, Tumor Biology, Journal of Surgical Research, PLOS ONE, and the Journal of Translational Medicine.
Dr. Delitto has earned numerous honors related to clinical excellence, teaching and research. He is board certified by the American Board of Surgery and a member of the Society of Surgical Oncology, American Association for Cancer Research and American Association of Immunologists.
His education includes a decade of postgraduate training in complex general surgical oncology, as well as a PhD in immunology with an emphasis on cancer biology. He completed a clinical fellowship at Johns Hopkins University and continued his research at the postdoctoral level in the laboratory of Dr. Elizabeth Jaffee. His research focus is on advancing the field of cancer immunology and harnessing his findings to improve immunotherapies.
He was the principal investigator of two studies examining the immune response to pancreatic cancer, including one funded by the National Cancer Institute.
Dr. Delitto has presented the findings of his research at conferences such as the American Association for Cancer Research, Society for the Immunotherapy of Cancer, American Association of Immunologists, American College of Surgeons, Academic Surgical Congress and Pancreas Club. In addition to cancer immunology, he has also presented work focused on cancer cachexia, surgical outcomes, translational experimental models and a variety of other oncologic topics.
He has published original work in Nature Communications, the Journal of the National Cancer Institute, Cancer Research, Clinical Cancer Research, and other high impact journals. He is also a reviewer for Annals of Surgery, Scientific Reports, Surgery, Tumor Biology, Journal of Surgical Research, PLOS ONE, and the Journal of Translational Medicine.
Dr. Delitto has earned numerous honors related to clinical excellence, teaching and research. He is board certified by the American Board of Surgery and a member of the Society of Surgical Oncology, American Association for Cancer Research and American Association of Immunologists.
View Full Biography
Professional Summary
Education & Certifications
- Board Certification: American Board of Surgery, Complex General Surgical Oncology (2022)
- Fellowship: Johns Hopkins University Surgery Program (2021) MD
- Residency: University of Florida Dept of General Surgery (2019) FL
- Board Certification: American Board of Surgery, General Surgery (2019)
- PhD Training: University of Florida Office of the Registrar (2016) FL
- Medical Education: University of Pittsburgh School of Medicine Registrar (2011) PA
Administrative Appointments
- John and Marva Warnock Faculty Scholar, Stanford University School of Medicine (2023 - Present)
Publications
-
Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection.
Delitto, D., Zabransky, D. J., Chen, F., Thompson, E. D., Zimmerman, J. W., Armstrong, T. D., … Jaffee, E. M. (2021). Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. Oncoimmunology, 10(1), 2001159. -
GSK3 suppression upregulates ß-catenin and c-Myc to abrogate KRas-dependent tumors.
Kazi, A., Xiang, S., Yang, H., Delitto, D., Trevino, J., Jiang, R. H., … Sebti, S. M. (2018). GSK3 suppression upregulates ß-catenin and c-Myc to abrogate KRas-dependent tumors. Nature Communications, 9(1), 5154. -
Prognostic Value of Clinical vs Pathologic Stage in Rectal Cancer Patients Receiving Neoadjuvant Therapy.
Delitto, D., George, T. J., Loftus, T. J., Qiu, P., Chang, G. J., Allegra, C. J., … Iqbal, A. (2018). Prognostic Value of Clinical vs Pathologic Stage in Rectal Cancer Patients Receiving Neoadjuvant Therapy. Journal of the National Cancer Institute, 110(5), 460–466. -
Human Pancreatic Cancer Cells Induce a MyD88-Dependent Stromal Response to Promote a Tumor-Tolerant Immune Microenvironment.
Delitto, D., Delitto, A. E., DiVita, B. B., Pham, K., Han, S., Hartlage, E. R., … Wallet, S. M. (2017). Human Pancreatic Cancer Cells Induce a MyD88-Dependent Stromal Response to Promote a Tumor-Tolerant Immune Microenvironment. Cancer Research, 77(3), 672–683. -
Targeting tumor tolerance: A new hope for pancreatic cancer therapy?
Delitto, D., Wallet, S. M., & Hughes, S. J. (2016). Targeting tumor tolerance: A new hope for pancreatic cancer therapy? Pharmacology & Therapeutics, 166, 9–29. -
Radiographic, Biochemical, or Pathologic Response to Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: Which Is Best?
Javadi, C., Chang, J., Forgo, E., Ahmad, M. U., Fisher, G. A., Chang, D. T., … Poultsides, G. A. (2022). Radiographic, Biochemical, or Pathologic Response to Neoadjuvant Chemotherapy in Resected Pancreatic Cancer: Which Is Best? ANNALS OF SURGICAL ONCOLOGY. SPRINGER. -
Surgical solution for a paraneoplastic neurodegenerative disorder
Muhammad, H., Strayve, D. G., Narayan, R. R., Blayney, D. W., & Delitto, D. (2022). Surgical solution for a paraneoplastic neurodegenerative disorder. TRAUMA SURGERY & ACUTE CARE OPEN, 7(1). -
Surgical solution for a paraneoplastic neurodegenerative disorder.
Muhammad, H., Strayve, D. G., Narayan, R. R., Blayney, D. W., & Delitto, D. (2022). Surgical solution for a paraneoplastic neurodegenerative disorder. Trauma Surgery & Acute Care Open, 7(1), e000928. -
First Recurrence of Synovial Sarcoma Presenting With Solitary Pancreatic Mass
Narayan, R. R., Charville, G. W., Delitto, D., & Ganjoo, K. N. (2022). First Recurrence of Synovial Sarcoma Presenting With Solitary Pancreatic Mass. CUREUS JOURNAL OF MEDICAL SCIENCE, 14(6). -
Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy.
Ivey, G. D., Shoucair, S., Delitto, D. J., Habib, J. R., Kinny-Koster, B., Shubert, C. R., … He, J. (2022). Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy. World Journal of Surgery. -
First Recurrence of Synovial Sarcoma Presenting With Solitary Pancreatic Mass.
Narayan, R. R., Charville, G. W., Delitto, D., & Ganjoo, K. N. (2022). First Recurrence of Synovial Sarcoma Presenting With Solitary Pancreatic Mass. Cureus, 14(6), e26356. -
Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin.
Foster, D. S., Januszyk, M., Delitto, D., Yost, K. E., Griffin, M., Guo, J., … Longaker, M. T. (2022). Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin. Cancer Cell. -
Age-related changes in pancreatic fibroblasts promote growth and progression of pancreatic cancer
Zabransky, D. J., Chhabra, Y., Fane, M. E., Delitto, D., Zimmermann, J. W., Jaffee, E. M., & Weeraratna, A. T. (2022). Age-related changes in pancreatic fibroblasts promote growth and progression of pancreatic cancer. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Mechanoresponsive Pancreatic Ductal Adenocarcinoma Cancer Associated Fibroblasts Shows an FAK-Dependent Subtype Divergent from Canonical Fibrotic TGFB-Pathway Dependence
Foster, D., Delitto, D., Januszyk, M., Yost, K., Griffin, M., Guo, J., … Longaker, M. (2023). Mechanoresponsive Pancreatic Ductal Adenocarcinoma Cancer Associated Fibroblasts Shows an FAK-Dependent Subtype Divergent from Canonical Fibrotic TGFB-Pathway Dependence. ANNALS OF SURGICAL ONCOLOGY. SPRINGER. -
Patterns of Recurrence After Poor Response to Neoadjuvant Chemotherapy in Gastric Cancer and the Role for Adjuvant Radiation.
Hui, C., Ewongwo, A., Lau, B., Fisher, G., Delitto, D., Poultsides, G., … Vitzthum, L. K. (2023). Patterns of Recurrence After Poor Response to Neoadjuvant Chemotherapy in Gastric Cancer and the Role for Adjuvant Radiation. Annals of Surgical Oncology. -
Desmoplastic stromal signatures predict patient outcomes in pancreatic ductal adenocarcinoma.
Mascharak, S., Guo, J. L., Foster, D. S., Khan, A., Davitt, M. F., Nguyen, A. T., … Longaker, M. T. (2023). Desmoplastic stromal signatures predict patient outcomes in pancreatic ductal adenocarcinoma. Cell Reports. Medicine, 101248. -
ASO Visual Abstract: Patterns of Recurrence after Poor Response to Neoadjuvant Chemotherapy in Gastric Cancer and the Role for Adjuvant Radiation.
Hui, C., Ewongwo, A., Lau, B., Fisher, G., Delitto, D., Poultsides, G., … Vitzthum, L. K. (2023). ASO Visual Abstract: Patterns of Recurrence after Poor Response to Neoadjuvant Chemotherapy in Gastric Cancer and the Role for Adjuvant Radiation. Annals of Surgical Oncology. -
Optimized Nuclei Isolation from Fresh and Frozen Solid Tumor Specimens for Multiome Sequencing.
Foster, D. S., Griffin, M., Januszyk, M., Delitto, D., Norton, J. A., & Longaker, M. T. (2023). Optimized Nuclei Isolation from Fresh and Frozen Solid Tumor Specimens for Multiome Sequencing. Journal of Visualized Experiments : JoVE, (200). -
Fibroblasts in the aged pancreas drive pancreatic cancer progression.
Zabransky, D. J., Chhabra, Y., Fane, M. E., Kartalia, E., Leatherman, J. M., Hüser, L., … Weeraratna, A. T. (2024). Fibroblasts in the aged pancreas drive pancreatic cancer progression. Cancer Research. -
Overexpression of Senescence-Associated Genes, SFN and CDC6, Correlates with Poor Survival in Patients with Stage II Hepatocellular Carcinoma (HCC)
Badshah, J., Subramanian, S., Melcher, M., Sasaki, K., Visser, B., Delitto, D., … Kirchner, V. (2024). Overexpression of Senescence-Associated Genes, SFN and CDC6, Correlates with Poor Survival in Patients with Stage II Hepatocellular Carcinoma (HCC). AMERICAN JOURNAL OF TRANSPLANTATION. ELSEVIER SCIENCE INC. -
Distal Pancreatectomy With and Without Celiac Axis Resection for Adenocarcinoma: A Comparison in the Era of Neoadjuvant Therapy
Daniel, S. K., Hironaka, C., Ahmad, M. U., Delitto, D., Dua, M., Lee, B., … Poultsides, G. (2024). Distal Pancreatectomy With and Without Celiac Axis Resection for Adenocarcinoma: A Comparison in the Era of Neoadjuvant Therapy. ANNALS OF SURGICAL ONCOLOGY. SPRINGER. -
Single cell pharmacogenic pipeline identifies novel opportunities in uterine leiomyosarcoma
Daniel, S. K., Foster, D., Nosrati, F., Korah, M., Fallah, M., Sun, B. J., … Delitto, D. (2024). Single cell pharmacogenic pipeline identifies novel opportunities in uterine leiomyosarcoma. ANNALS OF SURGICAL ONCOLOGY. SPRINGER. -
Natural history of undifferentiated pleomorphic sarcoma: Experience from the US Sarcoma Collaborative
Makris, E. A., Tran, T. B., Delitto, D. J., Lee, B., Ethun, C. G., Grignol, V., … Kirane, A. (2024). Natural history of undifferentiated pleomorphic sarcoma: Experience from the US Sarcoma Collaborative. JOURNAL OF SURGICAL ONCOLOGY. -
Hematoxylin and Eosin Architecture Uncovers Clinically Divergent Niches in Pancreatic Cancer.
Guo, J. L., Lopez, D. M., Mascharak, S., Foster, D. S., Khan, A., Davitt, M. F., … Longaker, M. T. (2024). Hematoxylin and Eosin Architecture Uncovers Clinically Divergent Niches in Pancreatic Cancer. Tissue Engineering. Part A. -
Circulating Tumor DNA in the Monitoring of Soft Tissue Sarcoma Treatment and Recurrence.
Sun, B. J., Li, A. Y., Hur, D. G., Zhou, M., Poultsides, G. A., Delitto, D. J., & Lee, B. (2024). Circulating Tumor DNA in the Monitoring of Soft Tissue Sarcoma Treatment and Recurrence. Annals of Surgical Oncology.
Practice Locations
Gastrointestinal (GI) Cancer Program in Palo Alto Palo Alto, CA
Palo Alto, CA
Gastrointestinal (GI) Cancer Program in Palo Alto
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereSarcoma Program at Blake Wilbur Building Palo Alto, CA
Palo Alto, CA
Sarcoma Program at Blake Wilbur Building
875 Blake Wilbur Drive
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(58 reviews)
Highly skilled and very personable.
I would recommend him to anyone. He is excellent and makes you feel soooo comfortable and at ease.
Greatest sense of humor which is so important in the healing process.
Dr Delitto is an Extremely Competent Surgeon!!! He saved my life and I will never forget him!!!
He is very nice and very informative. I liked him very much.
Great doctor
Awesome caring doctor
I had a great appointment Doctor Delitto and all of the staff were nice and answered all of our questions.
Excellent job and understandable
Really like Dr Delitto.He's very warm and caring.
He was great!
Dr Delitto is an amazing doctor who genuinely cares about his patients. He is thoughtful in his work and has a team of people who have provided me with excellent care. I can’t imagine going through my diagnosis without him as my surgeon.
Dr delitto is the best doctor at what he does thank you for all you have done for me and my family thanks you as well
Nice personality and listens to your concerns and questions.
Does not rush you.
He is excellent and very approachable!!!
He is a excellent Doctor, in my case!
He made me feel comfortable about the surger,and explained what he needs to do
Dr Delitto did not rush our visit. I felt completely at ease. I was very impressed ðŸ‘
He is very easy to talk to and shows a good deal of patient empathy.
excellent caring doctor.
Highly recommended
very knowledgeable and kind Dr made me feel very comfortable from the day I met him on first visit I’m extremely grateful he did such a well surgery and my post op was not bad at all thank you
Dr. Daniel Delitto is an especially caring and extremely skilled physician and surgeon.
Very professional, understood my concerns, I feel he’s going to give every effort in helping me fight this battle.
He is a very confident doctor who helps me understand my condition and gives me confidence about a condition that could actually be quite frightening.
He’s great! Good sense of humor, very thorough and extremely prepared and organized.
Excellent doctor.
Terrific on patient communication and surgical insight.
I felt extremely comfortable with Dr Delitto! He was warm and friendly. He made me feel like he really cares about me and what I’m going through and options for my tumor. He gave me hope and what a wonderful feeling that is!
I am so glad to have him as my Doctor!
Very good
I really like Dr delitto. He explained everything simply and answered all the questions I had
Very warm personality. I’m very comfortable with him.
Very informative explained well
Excellent surgeon. Compassionate physician. Positive outlook.
Dr.Delitto is an exceptional doctor. He is very knowledgeable and caring.
He completely answered all my questions, was very reassuring and gave me peace about proceeding with this surgery. He did not make me feel rushed. Very grateful for his clarity that this is the right procedure for me.
Dr Delitto is very friendly, doesn’t rush you, answers all questions and makes you feel confident in his recommendations
His a very excellent doctor.
Dr. Delitto is a great doctor. He is kind, compassionate and really listens. He always answers all of my questions. I am very happy to have him as my doctor as I deal with a difficult medical condition.
It was my first time meeting him. He seemed knowledgable and personable and feel confident we can find a plan to help some of my issues
excellent patient centered care
Excellent
Very good visit with Dr Delitto. Answered all my questions.
That he is an amazing doctor and person… really professional! I really trust him since my first appointment with him.
He answered all my questions and helped me understand the procedure I will be having. I really liked him. Very personable.
Excellent
Enjoyed meeting him.
Daniel Delitto is an incredibly skilled and caring doctor.
He has explained everything to us completely. Been very upfront on his thoughts. Giving us information when asked. Explained thoroughly what he wants done going forward and why. I am very happy with the attention to my case that he has given us. Thank you!
excellent
Dr Delitto was great. Very kind, listened very patiently to all of my questions and answered them as best he could.
Excellent in every way possible!
Best hospital ever.
He seems to care
He was very understanding and compassionate, answered all questions well, very knowledgeable.
Very good doctor and answer all my questions.
I really like Dr. Delitto. I feel that he is very thorough and very personable. He explained everything to my wife and I in language that was easy to process and understand. I would certainly recommend Dr. Delitto to family or friends.
Dr. Delitto is a very caring and encouraging physician and an extremely skillful surgeon. He is very easy to talk to, and is very considerate of family members. I would recommend him to anyone in need of surgical intervention.
Loved having the doctor explain about test results he had and procedure that needed to be done.
View More
Referring Physicians
PHYSICIAN HELPLINE
Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records